Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Alcohol-associated Liver Disease
What factors into your choice to use craving-related medications (e.g., baclofen, naltrexone, acamprosate, etc.) in the management of alcohol use disorder?
Do you continue them after a liver transplant?
Related Questions
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?
With the growth of non-alcoholic beverages (e.g., NA beer, liquor, etc), how do you approach a patient's consumption of these products in the setting of alcohol related liver disease?
How do you incorporate addiction medicine and counseling into your treatment plan for patients with alcohol associated liver disease?
How has the move away from a strict 6 month period of sobriety impacted your patient selection criteria for transplant of patients with alcohol associated liver disease?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
What is your endoscopic approach to the management of refractory GAVE in persistently anemic patients?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
How do you utilize urine sodium and potassium levels and ratios in diuretic optimization in patients with ascites?